论文部分内容阅读
目的:观察头孢克洛治疗下呼吸道细菌感染的疗效及安全性。方法:观察组给予头孢克洛20 mg.kg-1.d-1口服,3次/d。对照组静脉滴注β内酰胺类第3代头孢类抗生素头孢曲松30~80 mg.kg-1.d-1,1次/d。两组疗程均为1周。结果:观察组临床总有效率为92.06%,不良反应发生率4.7%;对照组总有效率93.10%,不良反应发生率11%。两组疗效比较差异无显著性(P<0.05)。结论:口服头孢克洛冲剂治疗急性下呼吸道感染疗效满意。
Objective: To observe the efficacy and safety of cefaclor in the treatment of lower respiratory tract bacterial infections. Methods: The observation group was given cefaclor 20 mg.kg-1.d-1 orally, 3 times / d. Control group intravenous infusion of β-lactam third-generation cephalosporin ceftriaxone 30 ~ 80 mg.kg-1.d-1,1 times / d. Two courses of treatment are 1 week. Results: The total effective rate in the observation group was 92.06% and the incidence of adverse reactions was 4.7%. The total effective rate in the control group was 93.10% and the incidence of adverse reactions was 11%. There was no significant difference between the two groups (P <0.05). Conclusion: The efficacy of oral cefaclor granules in treating acute lower respiratory tract infection was satisfactory.